EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY-NC 4.0

Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants

Eunice Stiboy iD, Mei Chan iD, Md Saiful Islam, Gemma L Saravanos iD, Kei Lui, Adam Jaffe, Nusrat Homaira iD

Pediatric Pulmonology · 2023

DOI: 10.1002/ppul.26324 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Eunice Stiboy und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, The University of Sydney, Camperdown, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Uniformity and compliance with clinical practice guidelines (CPGs) for use of palivizumab in preventing severe respiratory syncytial viral infection in Australian high‐risk infants remain unclear.

Methods

An online survey was conducted across the Australian and New Zealand Neonatal Network (ANZNN) to determine clinical practices around palivizumab. A literature search was also performed to identify and compare national and international guidelines.

Results

A total of 65 of 422 ANZNN members completed the survey. Respondents included 61 senior medical staff of consultants/staff specialists (78%) and four nursing staff (6%). According to the survey, infants most likely to be recommended palivizumab included preterm infants born

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalRespiratory Syncytial Virus InfectionsChildHumansInfantInfant, NewbornAntibodies, Monoclonal, HumanizedAntiviral AgentsAustraliaHospitalizationInfant, PrematurePalivizumabRespiratory Syncytial VirusesPractice Guidelines as Topic

Stichwörter der Autor:innen

PalivizumabRSVguidelineinfantsprophylaxis

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntiviral AgentsPalivizumab

Autor:innen und Institutionen

  • School of Public Health, The University of Sydney, Camperdown, Australia.
  • UNSW Medicine and Health, Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Sydney, Randwick, NSW, Australia.
  • National Center for Epidemiology and Population Health, ANU, Canberra, Australia.
  • Chidlren's Hospital Westmead Clinical School, The University of Sydney, Camperdown, Australia.
  • Susan Wakil School of Nursing and Midwifery, The University of Sydney, Camperdown, Australia.
  • Australian and New Zealand Neonatal Network, UNSW, Sydney, Sydney, Australia.

ORCID-Profile: Eunice Stiboy, Mei Chan, Gemma L Saravanos, Nusrat Homaira

Zitieren

APA

Stiboy, E., Chan, M., Islam, M. S., Saravanos, G. L., Lui, K., Jaffe, A., & Homaira, N. (2023). Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26324

Vancouver

Stiboy E, Chan M, Islam MS, Saravanos GL, Lui K, Jaffe A, et al. Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26324

BibTeX
@article{Stiboy2023,
  author = {Stiboy, Eunice and Chan, Mei and Islam, Md Saiful and Saravanos, Gemma L and Lui, Kei and Jaffe, Adam and Homaira, Nusrat},
  title = {Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants},
  journal = {Pediatric Pulmonology},
  year = {2023},
  doi = {10.1002/ppul.26324}
}
Kostenlos starten →